Latest News and Press Releases

Four out of 10 evaluable patients showed clinical response (PGA score ≤ 3), three of whom achieved complete closure of target lesionTreatment was well tolerated; no adverse events associated with dose...

JENA, Germany, Aug. 06, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will...

Severe COVID-19 trial enrollment reaches 299 patients; an independent data monitoring committee has recommended to continue the trial as planned after analyzing data from the first 180 evaluable...

JENA, Germany, June 17, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...

Proof-of-concept trial will evaluate vilobelimab alone and in combination with pembrolizumab JENA, Germany, June 08, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage...

JENA, Germany, May 21, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...

Severe COVID-19 trial enrollment reaches 178 patients; interim analysis expected in Q3 At the FDA’s suggestion, planning to request a Type A meeting to further discuss primary endpoint for the Phase...

U.S. IXPLORE Phase II trial achieved its objective; vilobelimab was shown to be safe and well tolerated in patients with ANCA-associated vasculitis when added to current standard of careEU IXCHANGE...

Target enrollment of 18 patients reached across three different dose groupsInterim results will be available by the end of 2021 with final results expected in 2022Initial positive data from the first...

Submitted a Special Protocol Assessment to the FDA for Phase III program evaluating vilobelimab in Hidradenitis Suppurativa (HS) in Q1 2021Phase III trial in Severe COVID-19 is ongoing and recruiting...